Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial

BACKGROUND: Our previous studies showed that GV1001 has various protective effects against β-amyloid and other stressors. Based on these findings, we hypothesized that GV1001 might have beneficial effects in patients with Alzheimer’s disease (AD). METHODS: A phase 2, double-blind, parallel-group, pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Koh, Seong-Ho, Kwon, Hyuk Sung, Choi, Seong Hye, Jeong, Jee Hyang, Na, Hae Ri, Lee, Chan Nyoung, Yang, YoungSoon, Lee, Ae Young, Lee, Jae-Hong, Park, Kyung Won, Han, Hyun Jeong, Kim, Byeong C., Park, Jin Se, Lee, Jee-Young, Kim, Sangjae, Lee, Kyu-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995588/
https://www.ncbi.nlm.nih.gov/pubmed/33771205
http://dx.doi.org/10.1186/s13195-021-00803-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995588/
https://www.ncbi.nlm.nih.gov/pubmed/33771205
http://dx.doi.org/10.1186/s13195-021-00803-w

Ejemplares similares